The Impact of Adjuvant Drug Therapy on Overall Survival in Patients with Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Urology Journal,
Vol. 22 No. 05 (2025),
11 November 2025
,
Page 217-224
https://doi.org/10.22037/uj.v22i.8540
Abstract
Purpose: Clear cell renal cell carcinoma (ccRCC), the dominant subtype of renal malignancy, has a rising global incidence and mortality. While surgery is the standard of care for localized cases, adjuvant therapy aims to improve outcomes in high-risk postoperative patients. To quantify the clinical value of adjuvant pharmacotherapy, this systematic review and meta-analysis assesses its effect on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in patients with ccRCC.
Materials and Methods: A comprehensive search of the Web of Science, Embase, Cochrane Library, and PubMed databases was conducted for articles published up to October 2024. The search used the English keywords “clear cell renal cell carcinoma,” “adjuvant drug therapy,” and “randomized controlled trials,” combined with a free-word search. Randomized controlled trials (RCTs) assessing the effectiveness of at least one adjuvant drug therapy in patients with ccRCC were included.
Results: The meta-analysis showed that adjuvant drug therapy did not result in a statistically significant improvement for OS or PFS compared with the control group. There was also no statistically significant difference in DFS (P > 0.05). This systematic review provides evidence on the impact of adjuvant targeted therapy on OS, DFS, and PFS for patients with clear cell renal cell carcinoma.
Conclusion: This study summarizes the effects of adjuvant drug therapy on OS, PFS, and DFS in ccRCC patients. The evidence from this meta-analysis can inform clinical decision-making, support risk stratification strategies, and encourage the integration of OS-driven endpoints in future trial designs, thereby providing valuable data for the treatment of ccRCC.
- Adjuvant drug therapy
- Clear cell renal cell carcinoma
- Ipilimumab
- Nivolumab
How to Cite
References
Chen R, Zhang Z, Hu B, Jiang M, Zheng P, Deng W, et al. Identification of the Expression and Clinical Significance of E2F Family in Clear Cell Renal Cell Carcinoma. Int J Gen Med. 2022;15:1193-212.
El-Zaatari ZM, Truong LD. Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update. Biomedicines. 2022;10.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
Yiu W, Chen J, Zhao B, Zhang W, Chen L, Liu H. The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Comput Math Method M. 2022;2022:7341294.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;390:1359-1371.
Patel HD, Kates M, Allaf ME. Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. Eur Urol Focus. 2020;6:3-6.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020;18:1160-70.
Laukhtina E, Quhal F, Mori K, Sari MR, Pradere B, Schuettfort VM, et al. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urol Oncol. 2021;39:764-73.
Raghubar AM, Roberts MJ, Wood S, Healy HG, Kassianos AJ, Mallett AJ. Cellular milieu in clear cell renal cell carcinoma. Front Oncol. 2022;12:943583.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385:683-94.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133-44.
Bedke J, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma. Eur Urol. 2025;87:491-496.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31.
Amaro F, Pisoeiro C, Valente MJ, Bastos ML, Guedes DPP, Carvalho M, et al. Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. Int J Mol Sci. 2022;23.
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115-25.
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. EAU Guidelines on Renal Cell Carcinoma: 2020 Update. Eur Urol. 2020.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthelemy P, et al. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2022;81:266-71.
Shah R, Botteman M, Solem CT, Luo L, Doan J, Cella D, et al. A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). Clin Genitourin Canc. 2019;17:356-65.
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752-9.
Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol. 2023;6:437-46.
Chamie K, Donin NM, Klopfer P, Bevan P, Fall B, Wilhelm O, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3:913-20.
Lara PJ, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, et al. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024;86:258-64.
Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012;118:6152-61.
Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401:821-32.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016;375:2246-54.
Massari F, Di Nunno V, Mollica V, Graham J, Gatto L, Heng D. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. Clin Genitourin Canc. 2019;17:e339-44.
Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. CUAJ. 2018;12:173-80.
Riaz IB, Faridi W, Husnain M, Malik SU, Sipra Q, Gondal FR, et al. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2019;94:1524-34.
Riaz IB, Siddiqi R, Islam M, He H, Riaz A, Asghar N, et al. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clin Cancer Inform. 2021;5:588-99.
Riveros C, Huang E, Ranganathan S, Klaassen Z, Rini B, Wallis C, et al. Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis. BJU Int. 2023;131:553-61.
- Abstract Viewed: 404 times
- 8540/pdf Downloaded: 172 times